Insight

Enrique Grande: Intravesical durvalumab shows promise for high-risk NMIBC after BCG failure

Enrique Grande/mdandersonhospiten.es

Jan 21, 2025, 16:07

Enrique Grande: Intravesical durvalumab shows promise for high-risk NMIBC after BCG failure

Enrique Grande, Head of Oncology at MD Anderson Cancer Center, shared a post on LinkedIn about a recent paper by Charalampos Fragkoulis et al. published in European Urology:

“Intravesical durvalumab (1000 mg every 6 weeks) shows promise for high-risk NMIBC after BCG failure.

Feasible administration with negligible toxicity.
Encouraging efficacy as a localized immune checkpoint inhibitor.
Intravesical delivery may surpass systemic approaches.”

“Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group”

Authors: Charalampos Fragkoulis, Aristotelis Bamias, Nikos Gavalas, Andreas Skolarikos, Athanasios Papatsoris et al.

Enrique Grande: Intravesical durvalumab shows promise for high-risk NMIBC after BCG failure

More posts featuring Enrique Grande.

Andreas Skolarikos Aristotelis Bamias Athanasios Papatsoris bladder cancer cancer Charalampos Fragkoulis Durvalumab Enrique Grande Hellenic GU Cancer Group Nikos Gavalas NMIBC Non-muscle-invasive Bladder Cancer OncoDaily Oncology

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

Karen Knudsen: Clinical trials are the most advanced form of cancer care

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results